00:26 , Jan 25, 2019 |  BC Week In Review  |  Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Jan. 23 in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia...
23:35 , Jan 23, 2019 |  BC Extra  |  Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Wednesday in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia and...
20:07 , Jul 25, 2018 |  BC Extra  |  Company News

Management Tracks: Albireo, ObsEva

Pediatric liver disease company Albireo Pharma Inc. (NASDAQ:ALBO) said CMO Paresh Soni will step down. He is succeeded by Patrick Horn, who was SVP of medical and clinical development at Orphan Technologies Ltd. (Rapperswil, Switzerland)....
22:12 , Sep 15, 2017 |  BioCentury  |  Finance

Orphan opportunity

Private equity giant KKR returned to co-lead BridgeBio Pharma LLC 's $135 million venture round, which could enable the Orphan play to double its pipeline in the next two years. KKR co-led the Sept. 13...
20:29 , Sep 15, 2017 |  BC Week In Review  |  Financial News

BridgeBio raises $135M round

On Sept. 13, BridgeBio Pharma (Palo Alto, Calif.) raised $135 million in an undisclosed venture round led by new investor Viking Global Investors and existing investor KKR. New investors AIG, Aisling Capital , Cormorant Capital...
22:59 , Sep 13, 2017 |  BC Extra  |  Financial News

BridgeBio raises $135M round

BridgeBio Pharma (Palo Alto, Calif.) raised $135 million in an undisclosed venture round led by new investor Viking Global Investors and existing investor KKR. New investors AIG, Aisling Capital , Cormorant Capital and Janus Funds...
07:00 , Sep 12, 2011 |  BioCentury  |  Politics, Policy & Law

Biodefense report card

Ten years after 9/11 and the subsequent anthrax attacks alerted America to the threat posed by bioterrorism, progress in developing and procuring vaccines and drugs to protect the civilian population has been frustratingly slow. An...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Financial News

Xanodyne Pharmaceuticals completes venture financing

Xanodyne Pharmaceuticals Inc. , Newport, Ky.   Business: Genitourinary, Neurology, Hematology   Date completed: 10/29/09   Type: Venture financing   Raised: $50 million   Investors: Longitude Capital Management; Skandia; Silver Point Capital; MPM Capital; AIG;...
01:10 , Oct 30, 2009 |  BC Extra  |  Financial News

Xanodyne raises $50 million

Xanodyne Pharmaceuticals Inc. (Newport, Ky.) raised $50 million in a private round led by Longitude Capital. New investors Skandia and Silver Point Capital joined existing investors MPM Capital; AIG Investments; Perseus-Soros Biopharmaceutical Fund; Blue Chip;...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Clinical News

Anthrax Immune Globulin regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Emergent BioSolutions' Anthrax Immune Globulin (AIG) to treat inhalation anthrax disease. The anthrax immune globulin, which was developed...